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Abstract
Background: The association of xenotropic murine leukemia virus (MLV)-related virus (XMRV) in prostate cancer and chronic
fatigue syndrome reported in previous studies remains controversial as these results have been questioned by recent data.
Nonetheless, concerns have been raised regarding contamination of human vaccines as a possible source of introduction of
XMRV and MLV into human populations. To address this possibility, we tested eight live attenuated human vaccines using
generic PCR for XMRV and MLV sequences. Viral metagenomics using deep sequencing was also done to identify the
possibility of other adventitious agents.
Results: All eight live attenuated vaccines, including Japanese encephalitis virus (JEV) (SA-14-14-2), varicella (Varivax),
measles, mumps, and rubella (MMR-II), measles (Attenuvax), rubella (Meruvax-II), rotavirus (Rotateq and Rotarix), and yellow
fever virus were negative for XMRV and highly related MLV sequences. However, residual hamster DNA, but not RNA,
containing novel endogenous gammaretrovirus sequences was detected in the JEV vaccine using PCR. Metagenomics
analysis did not detect any adventitious viral sequences of public health concern. Intracisternal A particle sequences closest
to those present in Syrian hamsters and not mice were also detected in the JEV SA-14-14-2 vaccine. Combined, these results
are consistent with the production of the JEV vaccine in Syrian hamster cells.
Conclusions: We found no evidence of XMRV and MLV in eight live attenuated human vaccines further supporting the
safety of these vaccines. Our findings suggest that vaccines are an unlikely source of XMRV and MLV exposure in humans
and are consistent with the mounting evidence on the absence of these viruses in humans.
Citation: Switzer WM, Zheng H, Simmons G, Zhou Y, Tang S, et al. (2011) No Evidence of Murine Leukemia Virus-Related Viruses in Live Attenuated Human
Vaccines. PLoS ONE 6(12): e29223. doi:10.1371/journal.pone.0029223
Editor: Fabrizio Mammano, INSERM, France
Received September 13, 2011; Accepted November 22, 2011; Published December 2 , 2011
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for
any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: As a US government institution, funding is provided by the US Congress. The funders had no role in study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: bswitzer@cdc.gov
Introduction
A gammaretrovirus, called the xenotropic murine leukemia
virus (MLV)-related virus (XMRV), has been reported in persons
with prostate cancer (PC), chronic fatigue syndrome (CFS), and
blood donors with PCR prevalences up to 67% [1,2]. A related
MLV was also reported in about 86% of CFS persons in a separate
study [3]. The finding of XMRV and MLV in humans is
controversial as subsequent studies have failed to confirm the
initial reports [1,4,5,6,7,8,9,10]. Recent data showing that XMRV
was generated in the laboratory during the passage of a human
prostate cancer xenograft in nude mice during the generation of
the XMRV-infected prostate cancer cell line 22Rv1 raises further
doubts about the association of XMRV with human disease [11].
The origin of MLV in humans has also been questioned by the
finding of reagents, human cell lines and specimens that are
contaminated with MLV sequences [12,13,14,15,16,17,18]. How-
ever, additional studies aimed at defining the prevalence of
XMRV and related viruses in humans and their association with
diseases using an array of diagnostic tests are currently in progress
[19].
MLVs are endogenous gammaretroviruses that constitute about
8–10% of the mouse genome and can cause leukemia, lymphoma,
and neurological disorders in mice [20]. XMRV shares about 96%
nucleotide identity with MLVs classified as xenotropic and which
replicate only in non-mouse cells [1]. Thus, while mice are the
likely species origin of MLV-related viruses, exposures that may
have led to possible cross-species infections may be diverse,
ranging from natural exposure to mice to possible exposures of
biologicals, such as vaccines [21]. Mice and other rodents have
been, or are currently used, in the production of vaccines. For
example, the first live polio vaccine was grown in mice and tested
on humans in 1950, smallpox, yellow fever, and rabies viruses
were cultured in the brains of mice for vaccine production and
several live, attenuated vaccines are produced on mammalian cell
lines from mice, pigs, chickens, and cats [22]. Thus, MLV may
have been introduced into vaccines during attenuation of the
master seed stock during successive passage in rodents or during
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2vaccine production from contaminated reagents or growth in
mouse or other rodent cell lines.
The Japanese encephalitis virus (JEV) vaccine (SA14-14-2,
Rongsheng, China) is an example of a live vaccine that was
attenuated via passage in rodents, including mouse brain, primary
hamster kidney (PHK) cells, mouse spleen and skin, Syrian
hamster (Mesocricetus auratus) spleens, and suckling mice skin [23].
Production of the SA-14-14-2 vaccine is done in the hamster PHK
cell line. According to the manufacturer, the master seed virus of
the SA-14-14-2 JEV vaccine and the PHK cell lines used for
vaccine production were shown to be free of adventitious agents
and pathogens. The SA-14-14-2 JEV vaccine has been used for
over 20 years and administered to over 300 million children in
China, South Korea, Nepal, and India.
Although the master seeds and cell substrates used for vaccine
production are prescreened for adventitious agents, newer
technologies, including sequence-independent amplification, fol-
lowed by ultra-deep DNA sequencing, and microarrays have
shown that some cell substrates and live-attenuated vaccines still
contain adventitious viruses, including endogenous retroviruses
like avian leukosis virus (ALV), and porcine circovirus [24].
Previous studies have also documented the presence of endoge-
nous avian retroviruses in currently used avian cell-derived
vaccines [25,26]. Endogenous retroviruses exist in all mammals
as proviral DNA integrated in the germ line of the host and are
passed from parent to offspring. Thus, endogenous retroviruses
cannot be eliminated from cell lines or live animals by pre-
screening. While most endogenous retroviruses are replication
defective, some exist as intact genomes that are capable of
expressing infectious virus.
We screened eight live attenuated human vaccines for XMRV
and related MLV and adventitious agents using PCR and
metagenomics. The eight vaccines included JEV (SA-14-14-2),
varicella (Varivax), measles, mumps, and rubella (MMR-II),
measles (Attenuvax), rubella (Meruvax-II), rotavirus (Rotateq
and Rotarix), and yellow fever virus. All eight vaccines were
negative for XMRV and closely related MLV sequences using
these two approaches. We found novel hamster genomic and
retrovirus sequences in the JEV vaccine mostly likely originating
from vaccine production in Syrian hamster cells. Our findings do
not support the hypothesis that vaccines are a possible source of
XMRV or MLV introduction into humans and are consistent with
accumulating evidence on the absence of these viruses in humans.
Results
Absence of MLV and XMRV sequences in live attenuated
vaccines by PCR testing
Total nucleic acids and particle-associated RNA from eight live
attenuated vaccines were tested for XMRV and MLV sequences
using a generic polymerase (pol) and a specific (gag) nested PCR test
capable of detecting at least 10 DNA and 100 RNA sequences per
reaction [2,3,27]. In addition, we used a new generic, quantitative
real-time PCR (qPCR) test capable of detecting protease (pro)
sequences of all MLV and XMRV with a reported sensitivity of 10
copies per reaction (fragment 1, Fig. 1) [28]. All eight vaccines
were negative for XMRV and MLV DNA and RNA sequences
using this combination of PCR tests, except the JEV vaccine which
was estimated to contain about 960 copies of MLV-like DNA
sequences/ml by using the qpro test (Tables 1 and 2). The MLV-
like DNA sequences detected in the JEV vaccine by qPCR were
confirmed by gel electrophoresis and sequence analysis. However,
the amount of MLV-like sequences in the qpro amplification
product appeared greater in the gel image than that quantified by
qPCR when compared to the qpCR assay standards (data not
shown). These results indicated detection of a variant with some
Figure 1. Schematic showing locations and sizes of endogenous retrovirus sequences detected in the live, attenuated Japanese
encephalitis virus (JEV) vaccine (SA-14-14-2) and in hamster cell lines. Primer positions are relative to an alignment of prototypical murine
leukemia viruses (MLV). Primer names and PCR fragments obtained are provided in parentheses. LTR, long terminal repeat; gag, group specific
antigen; pro, protease; pol, polymerase; env, envelope. Also shown is the 91-bp overlap region used for phylogenetic analysis of all PCR-amplified
fragements. Quantitative PCR with the Taqman primers Pro-UNV-F1 and Pro-UNV-R1 were used to originally detect gammaretroviruses in the JEV
vaccine and hamster cell line DNA (fragment 1, 161-bp). Four additional primer sets were used to amplify larger gammaretrovirus sequences for
further genetic characterization (Fragments 2–5). Nested PCR was used for obtaining fragments 3–5 and all amplified sequences were about 950-bp
in length. Only the inner most primer name combinations are shown. The primers PRO-UNV-OF 59TAGGGAGGTC AGGGTCAGGAGC39 and PRO-UNV-
OR 59GGAAAGAGTGRGTGACCT TACCGGT39 were used to amplify a second fragment (283-bp). The primary PCR amplification for fragment 3 used the
primers PRO-UNV-F1 and XPOLIR 59AAGTGGCGG CCAGCAGTAAGTCAT39, while the outer primers for fragments 4 and 5 were PRO-UNV-OF and
XPOLIR. The internal primers for fragments 3 and 4 were PRO-SA-IF1 59GAGCAACC AGTCACCTTCCTA39 and POL-IRM 59TCTGGGTGCTGGATCCGGAA39,
while the internal primers for fragment 5 were PRO-UNV-IF2 59 GGGCGCCCRGTCACCTTCCTG39 and POLIRM.
doi:10.1371/journal.pone.0029223.g001
XMRV/MLV Not Found in Human Vaccines
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the qPCR assay. Indeed, analysis of this 91-bp pro sequence
identified a distinct gammaretrovirus that is equidistant from
murine endogenous retroviruses (mERVs), XMRV, and MLV
sharing only 72–75% nucleotide and amino acid identity (data not
shown).
Table 1. Identification of Hamster DNA and Retroviruses in Eight Live, Attenuated Human Virus Vaccines.
Vaccine Virus Manufacturer Lot Nos.
Virus
Preparation Animal Passage
Metagenomics
analysis (non-
vaccine viruses)
1
XMRV/MLV
PCR
Murine
DNA PCR
SA-14-2-2 Japanese
encephalitis
Rongsheng 201002A014-3
200906A087-1
live,
attenuated
Primary hamster
kidney cells, mice,
hamsters, primary
chick embryo
Autographa c.
nucleopolyhedrous
virus, HERV-H
Pos
2 Syrian hamster
DNA
Varivax varicella Merck 1526X live,
attenuated
embryonic
guinea pig
None Neg NT
3
MMR-II measles,
mumps,
rubella
Merck 1732X live,
attenuated
chick embryo cell
culture
None Neg NT
Attenuvax measles Merck 1440X live,
attenuated
chick embryo cell
culture
avian leukosis
virus
Neg NT
Meruvax-II rubella Merck 1198X live,
attenuated
none None Neg NT
RotaTeq rotavirus Merck 1724X live,
attenuated
MA104 (rhesus
macaque kidney),
Vero cells (AGM
kidney)
None Neg NT
Rotarix rotavirus GlaxoSmithKline A41FA799A live,
attenuated
Vero cells (AGM
kidney)
porcine circovirus Neg NT
Yellow
Fever
yellow
fever virus
Sanofi Pasteur UF430AA-5188 live,
attenuated
embryonated
chicken eggs
None Neg NT
1Metagenomic results for vaccines other than JEV were reported previously [24].
2Distinct gammaretrovirus sequences were obtained that were equidistant from MLV and XMRV.
3Not tested.
doi:10.1371/journal.pone.0029223.t001
Table 2. Detection of Japanese encephalitis virus (JEV) RNA, hamster endogenous retrovirus (ERV) DNA, and hamster genomic
DNA in the live, attenuated JEV vaccine (SA-14-14-2).
JEV SA-14-14-2
PCR Assay Nuclease
12(copies/ml) Nuclease+(copies/ml)
JEV RNA 4610
5 4610
5
Murine mtDNA (MCOX2) negative negative
IAP-pol DNA
2
(Syrian hamster + murine specific) 6.32610
10 1.94610
4
IAP-pol DNA
(Chinese hamster specific) negative negative
MLV RNA (qpro)9 . 6 610
2 negative
Hamster ERV RNA (qpro-based)
3 2.4610
6 negative
MLV RNA (ext-qpro)
4 positive negative
Hamster ERV RNA (ext-qpro-based)
5 2.1610
7 negative
MLV RNA (qgag) negative negative
MLV RNA (nested gag) negative ND
6
MLV RNA (nested pol) negative ND
1Viral filtrates treated with (+) or without (2) DNase and RNase.
2IAP, intracisternal A particle; pol, polymerase.
3Primers were based on amplicons generated with MLV quantitative protease (qpro) assay.
4ext, extended qpro assay and is equivalent to Fragment 2 in Fig. 1.
5Primers were based on amplicons generated with extended qpro assay.
6ND, not done.
doi:10.1371/journal.pone.0029223.t002
XMRV/MLV Not Found in Human Vaccines
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retrovirus and genomic sequences in JEV vaccines
To confirm the presence of the distinct gammaretrovirus
sequence in the JEV vaccine we designed a new qPCR test
specific for the detection and quantification of this sequence. Using
this test we estimated that the JEV vaccine contained 2.4610
6
copies/ml of this sequence (Table 2). To obtain longer sequences
for further viral characterization, we designed additional generic
primers flanking the qpro primers that are based on a nucleotide
alignment of MLV and XMRV complete genomes (fragment 2,
Fig. 1). We used these new pro primers to test nucleic acids from
the JEV vaccine. In addition, we tested DNA from Chinese
(Chinese hamster ovary, CHO) and Syrian (baby hamster kidney,
BHK) hamster cell lines since the JEV vaccine is produced in
hamster cells [23,29]. Longer pro sequences 200–235-bp in length
were detected in the JEV vaccine while 235-bp sequences were
amplified from the CHO and BHK cell lines, after removal of the
primer sequences. BLAST analysis showed that these longer pro
sequences in the vaccine and BHK were equidistant (,80%
nucleotide identity) from MLVs while those from the CHO cell
line were 94% identical to a transcriptionally active endogenous
retrovirus (Genbank U09104) found in Chinese hamsters (Cricetulus
griseus). Interestingly, these 200–235-bp pro sequences were distinct
from the 91-bp pro sequences sharing only 68–75% nucleotide
identity. Phylogenetic analysis of 82-bp containing the overlapping
regions of the 91-bp and 200–235-bp pro sequences confirmed
these genetic relationships and showed that these sequences are
distinct from MLV and XMRV and were closer in identity to
gammaretroviruses in the Chinese (CHO) and Syrian hamster cell
lines (BHK and HAK) (Fig. 2a).
We next designed additional forward PCR primers based on the
consensus qpro and the 200–235-bp pro vaccine sequences and new
generic reverse primers based on MLV and XMRV prototype pro-
pol sequences and applied these to the JEV vaccine and hamster
cell line nucleic acids to obtain longer and more phylogenetically
informative sequences (Fig. 1). A total of three different primer
combinations were used (Fig. 1) which generated three different
groups of DNA sequences 950-bp in length (fragments 3–5) from
the HAK cell line DNA and the JEV vaccine and all were distinct
from the 92-bp pro sequences. These pro-pol sequences were cloned
and analyzed and determined to be equidistant from other murine
retroviruses sharing only 70% nucleotide identity and were 77%
identical to each other. Phylogenetic analysis of an alignment
containing 910-bp of the 950-bp fragments alone or with the
overlapping pro regions (82-bp) confirmed that these new pro-pol
sequences are distinct from other gammaretroviruses in rodents
and other mammals (Fig. 2). When all five PCR fragments were
aligned and analyzed, six different gammaretrovirus phylogenetic
lineages were inferred (Fig. 2a). The first lineage included the
original qpro (Fragment 1) sequences that were distinct from
MLV, XMRV and other gammaretroviruses, including those
found in the JEV vaccine and hamster cell lines. The second
lineage contained fragment two sequences from the JEV vaccine
and Syrian hamster cell line, BHK, while the third lineage only
contained gammaretrovirus sequences from the Chinese hamster.
Lineage four contained distinct JEV (fragment 3) and Syrian
hamster sequences from the cell line HAK, while the fifth lineage
consisted of JEV fragment 4 and 5 sequences and distinct Syrian
hamster cell line (HAK) gammaretrovirus sequences. The sixth
lineage was composed of a divergent JEV sequence using the
fragment three PCR primers and a third set of Syrian hamster
sequences obtained from the HAK cell line. The sixth lineage was
also the most divergent, sharing a common ancestor with MLV/
XMRV, RaLV, FeLV, and the other hamster and JEV
gammaretrovirus sequences (Fig. 2a).
To further characterize the hamster and JEV gammaretro-
viruses, we phylogenetically analyzed the larger 910-bp alignment
consisting of only the fragment 3 to 5 sequences and the
appropriate reference sequences (Fig. 2b). Like the phylogenetic
analysis of the shorter 82-bp fragments, two distinct fragment 3
lineages and a single lineage containing the fragment 4 and 5 JEV
and hamster sequences were inferred. The two groups of 910-bp
pro-pol sequences from the JEV vaccine and HAK DNA containing
fragments 3 to 5 were also distinct from, but clustered with the
endogenous retrovirus (Genbank U09104) found in Chinese
hamsters (Cricetulus griseus) (Fig. 2b). The additional 910-bp pro-pol
fragment 3 sequences clustered more closely with rat leukemia
viruses (RaLV) but with moderate bootstrap support (Fig. 2b). All
three 910-bp pro-pol sequence lineages also contained sequences
from the HAK Syrian hamster cell line with strong bootstrap
support suggesting they are all of hamster origin (Fig. 2b). 950-bp
pro-pol sequences were not detected in the BHK and CHO cell line
DNAs using these primer combinations. The finding of highly
divergent gammaretrovirus sequences using these pro-pol primer
combinations is consistent with the detection of endogenous
retroviruses present in hamster DNA.
We evaluated these new sequences for open reading frames
(ORFs) indicative of intact viral genomes with replication
potential. The two different, 91-bp qpro sequences (fragment 1)
and all 950-bp pro-pol fragment 4 and 5 sequences in the JEV SA-
14-14-2 vaccine contained ORFs. In contrast, a single distinct
fragment 3 sequence found in the JEV vaccine and three HAK
pro-pol fragment 3 sequences (950-bp) that clustered weakly with
rat leukemia virus RaLV were all defective. A mixture of cloned
sequences with ORFs and defective ORFs were present in the
second class of fragment 3 pro-pol sequences (950-bp) from the SA-
14-14-2 vaccine and HAK cell line (71% and 50%, respectively).
Almost 69% of the fragment 2 pro sequences in the SA-14-14-2
vaccine and all BHK and CHO sequences were defective. Thus,
the majority of the cloned gammaretrovirus sequences detected in
the attenuated JEV vaccine and hamster cell lines were defective
in the subgenomic regions examined.
To investigate whether the retroviral sequences in the JEV
vaccines originated from endogenous proviral elements present in
DNA or were particle-associated RNA, we PCR-tested viral
filtrates that were first treated with and without nucleases. In the
presence of nucleases only JEV viral RNA was detected in the
filtrates indicating that the gammaretrovirus sequences in this
vaccine were not particle associated. Testing particle-associated
RNA using primers specific for the five new classes of
gammaretrovirus sequences identified in the vaccine yielded
negative results (Table 2) confirming that these sequences are
not particle-protected and likely represent genomic DNA from the
hamster cell substrate in which the vaccine was grown (Table 1).
Furthermore, essentially equivalent amounts of pro signals were
obtained when vaccine nucleic acids were tested by RT-PCR with
and without reverse transcriptase documenting retroviral DNA in
these extracts (data not shown). However, the presence of particle-
associated JEV RNA in the two vaccines was confirmed by the
detection of 4610
5 copies/ml JEV in both the untreated and the
nuclease-treated SA-14-14-2 vaccine filtrates. The attenuated JEV
vaccine was also negative for murine mtDNA and IAP sequences
but was positive for Syrian hamster, but not Chinese hamster, IAP
sequences (,4610
8 copies/ml) using new real-time PCR tests that
detect murine and hamster IAPs (Table 2). These new IAP tests
are extremely sensitive for detecting mouse DNA contamination in
a specimen and can detect 10 attograms of mouse DNA in a
XMRV/MLV Not Found in Human Vaccines
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residual Syrian hamster IAP DNA sequences even after filtration
and nuclease treatment of vaccine material demonstrate the
sensitivity of this new IAP assay for detecting low levels of IAP
DNA. These results most likely reflect incomplete digestion of
DNA in the material (Table 2). Combined with the presence of
endogenous hamster retrovirus DNA sequences, the IAP results
further demonstrate that the JEV SA-14-14-2 vaccine contains
residual hamster and not mouse DNA.
Absence of adventitious agents in attenuated JEV
vaccines by metagenomics analysis
We have previously shown by metagenomics analysis that the
attenuated Attenuvax measles contained viral particle-associated
RNA for ALV and endogenous avian retrovirus (EAV) [24].
Likewise, yellow fever and MMR-II vaccines, also made in chick
embryo cells, were previously found to contain particles with ALV
and EAV RNA [25,26]. The rotavirus vaccine Rotarix was shown
to contain porcine circovirus 1 (PCV1) [24] while PCR studies
showed RotaTeq to contain low levels of PCV1 and PCV2
(http://www.ncbi.nlm.nih.gov/pubmed/21569811). Using viral
metagenomics and a BLASTx E score cutoff of 0.001 to any viral
sequences we found no evidence of adventitious viruses in the live,
attenuated JEV (SA-14-14-2) (Table 1). A total of 1993
pyrosequence reads of over 100 nucleotides in length were
generated. These sequences included 48 contigs containing 281
reads that were identified as JEV. One near perfect read was
identical to Autographa californica nucleopolyhedrovirus, which is a
Figure 2. Identification of novel hamster endogenous gammaretrovirus sequences in the live attenuated Japanese encephalitis
virus (JEV) vaccine (SA-14-14-2). (a) Phylogenetic inference of 91-bp overlapping (final alignment length is 82-bp) gammaretrovirus DNA
sequences PCR-amplified from the JEV SA-14-14-2 vaccine and hamster cell lines (baby hamster kidney (BHK) and Chinese hamster ovary (CHO)) using
five different PCR assays. (b) Phylogenetic inference of 910-bp gammaretrovirus DNA sequences PCR-amplified from the JEV SA-14-14-2 vaccine and
HAK using three different PCR assays. The new sequences were phylogenetically compared to prototypical gammaretroviruses (GenBank accession
numbers in parentheses). MLV, murine leukemia virus; mERV, mouse endogenous retrovirus; FeLV, feline leukemia virus; RaLV, rat leukemia virus;
PtrogCERV, Pan troglodytes chimp endogenous retrovirus; GaLV, gibbon ape leukemia virus; KoaRV, koala retrovirus; PERV, porcine endogenous
retrovirus. XMRV sequences coded with VP and WPI are from persons with prostate cancer and chronic fatigue syndrome, respectively. X followed by
a number in parentheses indicates the number of identical sequences obtained for that fragment. Asterisks indicate sequences without open reading
frames. The MLV/XMRV and PERV branches were collapsed to fit the trees to single pages. Stability of the tree topology was tested using 1000
bootstrap replicates in both neighbor joining (NJ) and maximum likelihood (ML) methods. Bootstrap values .60 are shown (NJ/ML). New sequences
(fragments 1–4) from the JEV vaccine and hamster cell lines are in light blue and red text, respectively. Fragment 5 sequences amplified from the JEV
SA-14-14-2 vaccine are in dark blue text.
doi:10.1371/journal.pone.0029223.g002
XMRV/MLV Not Found in Human Vaccines
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insect pests and therefore most likely represents an environmental
contaminant. A 365-bp sequence with 99% nucleotide identity to
a human genomic region (GenBank accession no. AJ289710)
annotated as the human endogenous retrovirus type H was also
present in the JEV vaccine and most likely represents human DNA
contamination (Table 1). The inability of the metagenomics
analysis to detect the novel gammaretrovirus and hamster IAP
sequences reflects that these DNAs are not particle-associated.
Discussion
Despite the production of most strains of attenuated viruses on
primary animal-derived cells, live attenuated vaccines are safe,
inexpensive, and highly effective at reducing mortality and
morbidity from numerous diseases, and thus are used worldwide.
We tested eight live attenuated vaccines used globally to prevent
viral diseases. We found no evidence of either XMRV or MLV in
all eight vaccines using sensitive PCR testing for both viral RNA
and DNA sequences. We also show by ultra-deep sequencing of
particle-protected nucleic acids the absence of XMRV and MLV
in these vaccines. Thus, our data do not support the hypothesis
that these vaccines are a possible source of human exposures to
XMRV or MLV. These results are consistent with the production
of all these vaccines in non-mouse cells which substantially reduces
the risks of adventitious endogenous murine retroviruses.
There are other mouse-derived biological products that may be
at a higher risk of carrying MLV, such as monoclonal antibodies
(mAbs) that are used in humans for the treatment of cancer,
inflammatory, and autoimmune diseases [30]. Indeed, mouse
hybridomas that have been shown to be contaminated with
endogenous xenotropic MLVs [30], but the production of mouse
mAbs for clinical use requires purification steps that inactivate and
remove viral particles. Our study is also limited by the testing of
only eight vaccines and does not include other live attenuated
vaccines that have a history of passage in rodents, such as early
versions of the oral polio vaccine. We also did not test master virus
seed stocks (MVSS) and master cell banks (MCB) used in the
manufacture of the live attenuated vaccines from our study since
these materials were not readily available. Nonetheless, our testing
of vaccines used on humans was a more direct public health risk
assessment for adventitious agents that vaccine recipients may
have been exposed to compared to MVSS and MCB. Further-
more, the recent finding that XMRV originated as a laboratory
artifact during passaging of a prostate tumor xenograft in inbred
mice [11], the ability of human serum to inactivate MLV, and the
accumulating evidence from a large number of epidemiologic
studies showing the absence of XMRV or MLV in humans, all
cast doubts on the links of XMRV or MLV to prostate cancer and
CFS and their endemicity in human populations
[4,5,10,14,15,16,17,28,31,32,33,34]. Likewise, the proposed labo-
ratory origin of XMRV in the 22Rv1 cell line around 1996
suggests this virus could not have contaminated vaccines prior to
that date [11].
Although we did not find XMRV or MLV in any of the eight
vaccines, our data reveal that the live attenuated JEV vaccine (SA-
14-14-2) contains multiple hamster genomic DNA and endoge-
nous gammaretrovirus sequences that are distantly related to
MLV. Phylogenetic analysis showed that these sequences most
likely originated from Syrian and not Chinese hamsters, which is
consistent with the reported production history of the JEV SA-14-
14-2 vaccine in primary hamster kidney and Syrian hamster
spleen [23]. Importantly, specific PCR showed that these
sequences are not particle associated, which is consistent with
the metagenomics testing, and likely reflects genomic material
present in the hamster substrate cells in which the vaccine is
produced. Cell substrate DNA is commonly found in vaccines and
is unlikely to cause safety risks. Other live attenuated JEV vaccines
that are not produced in rodents are currently in preclinical and
clinical trials and have demonstrated good immunogenicity and
are apparently safe [29,35].
Conclusions
We found no evidence of XMRV or MLV in eight globally used
live attenuated vaccines and thus our results do not support the
hypothesis that these vaccines contributed to the iatrogenic
introduction of XMRV or MLV into the human population and
are in agreement with the accumulating evidence on the absence
of these viruses in human populations. We identified residual
hamster DNA containing multiple endogenous gammaretrovirus
sequences, but not retroviral RNA, in the JEV vaccine and show
that these sequences are of Syrian hamster origin consistent with
the production history of the vaccine.
Methods
Vaccines
Single dose, live attenuated SA 14-14-2 (Rongsheng; lot
nos. 200906A087-1 and 201002A014-3) JEV vaccines were stored
at 4uC and were re-suspended in the supplied 1.0 ml PBS.
Additional lyophilized live attenuated vaccines, as previously
described [24], were resuspended in 200 ml of manufacturer-
appropriate sterile diluent (Merck; lot no. 4089) or sodium
chloride solution (Sanofi Pasteur; lot no. UF198AB). Rotarix
(rotavirus, GlaxoSmithKline [GSK]; lot no. A41XA799A) and
Rotateq (rotavirus; Merck; lot no. 1724X) were resuspended in a
1-dose volume of accompanying oral diluent. A total of 200 mlo f
Meruvax (rubella; Merck; lot no. 1198X), Attenuvax (measles;
Merck, lot no. 1440X), YF-VAX (yellow fever; Sanofi Pasteur; lot
no. UF430AA-5188), MMR-II (measles, mumps, rubella; Merck;
lot no. 1732X), Rotateq, or Varivax (varicella virus; Merck; lot
no. 1526X) was filtered through a 0.45 mM filter (Millipore).
Viral particle purification and nucleic acid extraction
Vaccines were passed through a 400 nm filter and filtrate
containing viral particles was treated with a mixture of DNase and
RNase to remove exogenous, unprotected nucleic acids as
described previously [24]. Particle-associated nucleic acids were
then prepared using a QIAamp viral RNA extraction kit (Qiagen).
Nucleic acids were also extracted directly from the JEV vaccine
using the QIAamp viral RNA Mini extraction kit (Qiagen).
Virus-specific PCR for MLV, XMRV, and JEV
Both MLV-generic and XMRV-specific PCR tests were used to
screen the vaccine nucleic acids. Nested and real-time PCR tests
were used to generically detect MLV and XMRV gag and pro
sequences, respectively. The gag PCR test used the primers 419F
and 1154R in the primary amplification and GAG-I-F/GAG-I-R
for the nested PCR reaction [2,3,27]. The pol PCR test used the
primers XPOL-OF and XPOL-OR in primary and XPOL-IF and
XPOL-IR in the nested PCR reactions [27]. The quantitative
real-time PCR test in the protease (pro) region, called qpro, used the
Taqman primers Pro-UNV-F1 and Pro-UNV-R1 and probes Pro-
UNV-P1C and Pro-UNV-PR1 [28] (Fig. 1). The XMRV and
MLV generic gag quantitative real-time PCR test was performed
with the primers GAG-UNV-F1, 59AGGTAGGAACCACCTA-
GTYC39 and GAG-UNV-R1, 59GTCCTCAGG GTCATAAG-
GAG39 and probes GAG-UNV-P1C, 59FAMAGCGGGTCTC-
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CTTTTACCTTGGCCAAATTGGTGGG39BHQ1. JEV RNA
was detected using the Taqman primers and probes JE-multi-
forward and JE-multi-reverse and Multi-probe, as previously
described [36].
Metagenomics analysis of live, attenuated vaccines
Viral cDNA synthesis and random PCR amplification were
performed as previously described [24]. Briefly, 100 pmol of
primer consisting of an arbitrarily designed 20-base oligonucleo-
tide followed by a randomized octamer (8N) sequence at the 39
end was used in a reverse transcription (RT) reaction (Superscript
III; Invitrogen). Two distinct primers containing different 20-base
fixed sequences were used in two separate RT reactions targeting
the virus-enriched nucleic acids from the live-attenuated JEV
vaccine. A single round of DNA synthesis was then performed
using Klenow fragment polymerase (New England Biolabs), and
then PCR amplification of double-stranded DNA using a primer
consisting of only the 20 fixed bases was performed. Independent
duplicate PCRs were performed for each random primer,
generating a total of 4 separate reactions. Random PCR DNA
products were pooled and separated on an agarose gel, and
fragments from 500 bp to 1,000 bp were excised and extracted.
DNA was sequenced using GS FLX Titanium reagents.
Sequence read classification
The 454 sequence reads were trimmed of their random PCR
primer sequences and assembled into longer contigs using the
program Sequencher (Genecodes), with an overlap set as 95%
similarity over 35-bp to merge fragments. The contigs and singlets
greater than 100-bp were compared to the NCBI nonredundant
nucleotide and protein databases using BLASTn and BLASTx,
respectively. Viral sequences were classified based on their best
alignment E value and those with values ,10e–3 were deemed
unclassifiable.
Cell line DNA
Syrian baby hamster kidney (BHK), Syrian hamster kidney
(HAK), and Chinese hamster ovary (CHO) cryopreserved cell
lines were obtained from the CDC Biologics Branch and DNA was
extracted using the Qiagen Flexigene DNA kit.
Identification of novel hamster gammaretrovirus
sequences in the JEV vaccines
To further characterize the gammaretrovirus sequences identi-
fied in the JEV SA-14-14-2 vaccine additional PCR primers were
designed based on an alignment of endogenous murine and
hamster retrovirus sequences available at GenBank and the new
sequences obtained with the qpro primers and subsequent
amplicons. The primers PRO-UNV-OF 59TAGGGAGGTC
AGGGTCAGGAGC39 and PRO-UNV-OR 59GGAAA-
GAGTGRGTGACCT TACCGGT39 were used to amplify a
second fragment (283-bp) surrounding the qpro sequences from the
SA-vaccine and BHK and CHO cell line DNAs (Fig. 1). To
increase the sensitivity of detecting divergent murine or hamster
gammaretroviruses we used the following nested PCR primer
combinations to amplify three additional fragments about 950-bp
in size from the JEV SA-14-14-2 vaccine and HAK cell line DNA
(Fig. 1). The primary PCR amplification for fragment 3 used the
primers PRO-UNV-F1 and XPOLIR 59AAGTGGCGGCCAG-
CAGTAAGTCAT39, while the outer primers for fragments 4 and
5 were PRO-UNV-OF and XPOLIR. The internal primers for
fragments 3 and 4 were PRO-SA-IF1 59GAGCAACCAGT-
CACCTTCCTA39 and POL-IRM 59TCTGGGTGCTGGAT-
CCGGAA39, while the internal primers for fragment 5 were
PRO-UNV-IF2 59 GGGCGCCCRGTCACCTTCCTG39 and
POLIRM (Fig. 1). The Expand High Fidelity PCR System
(Roche) was used for the primary amplification and Amplitaq
(ABI) for the nested PCR. 25 ul of extracted nucleic acids or
100 ng cell line DNA were used as templates in the primary PCR
amplification. Forty cycles of each round of PCR was done using
95uC for 30 sec, 50uC for 30 sec, and 72uC for 1 min.
PCR detection of mouse and hamster DNA
contamination
Mouse mitochondrial DNA (mtDNA) and intracisternal A
particle (IAP) sequences were detected using the primers
MCOX2F2 and MCOX2R1 and probes MCOX2PR1 and
MCOX2P1 and IAP-F and IAP-R using the conditions previously
reported [16,28]. Given that the JEV SA-14-14-2 vaccine was also
passed in hamsters we also designed two new real-time PCR tests
that generically detect mouse and Syrian hamster IAP or
specifically detect Chinese hamster (CHO) IAP pol sequences.
The generic IAP primers and probes are IAP-MH-POLF2: 59
GCCTCAYATGTG ATTCAACATTG 39 and IAP-MH-
POLR2: 59 TTGRGASGTATAWGCTGGT CCATT 39 and
IAP-MH-POL P2: 59 FAM TTGAGGCMTGGAGTGCT-
TGGGGRAAACCCAGA 39BHQ1, respectively. The CHO-
specific IAP primers and probe are IAP-MH-POLF3
59GCCGCGCATGTGAT TCAACACTG39, IAP-MH-POLR3
59 TTGAGAGGTATAAGCCGGCCCAT39, and IAP-MH-
POLP3 FAM59TAGAGGCTTGGGGTGCCTGGGGTAAA-
CCTCAT39BHQ1. The assay was performed with a hot start at
95uC for 9 min followed by 55 cycles of PCR at 95uC for 30 sec
and 62uC for 30 sec. This assay was 1000X more sensitive in
detecting IAP sequences in mouse DNA than that using the IAP-F
and IAP-R primers though both and the mtDNA PCR tests could
detect 1 copy each in a background of 1 ug of human DNA (data
not shown).
Sequence analysis
PCR products were purified with QiaQuick PCR or gel
purification kits (Qiagen, Valencia, CA) and were directly
sequenced on both strands by using ABI Prism BigDye terminator
kits and an ABI 31306l sequencer (Foster City, CA) or following
cloning in the TOPO vector (Invitrogen). Initial sequence identity
was determined using BLAST analysis at the National Center for
Biotechnology Information web server (http://blast.ncbi.nlm.nih.
gov/Blast.cgi) using either the megablast or blastn search options.
Sequences were aligned with those retrieved from the BLAST
analysis with the highest nucleotide identity, and other MLV
prototypes available at GenBank, using Clustal W in the MEGA
v5.03 program (http://megasoftware.net/). Following manual
editing and removal of indels, substitution models and phyloge-
netic relationships were inferred using the neighbor joining (NJ)
method implemented in MEGA v5.03. Phylogenies were also
inferred using the program PhyML plugin in the Geneious
software package v5.3.6 (www.geneious.com) that implements the
fast maximum likelihood (ML) method. Support for the branching
order was evaluated using 1,000 nonparametric bootstrap
replicates.
Nucleotide sequence accession numbers
The new hamster gammaretrovirus pro-pol sequences generated
in the current study are available at GenBank with accession
numbers JN652837–JN652873. An alignment of the 91-bp pro
XMRV/MLV Not Found in Human Vaccines
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does not accept sequences less than 200-bp in length.
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